{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:39:01Z","timestamp":1790962741661,"version":"4.1.0"},"reference-count":233,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Key Scientific Research Project of Higher Education of Henan  Province","award":["23A310010"],"award-info":[{"award-number":["23A310010"]}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["222300420515"],"award-info":[{"award-number":["222300420515"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["252300421392"],"award-info":[{"award-number":["252300421392"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["232300420019"],"award-info":[{"award-number":["232300420019"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Open Program of Henan Key Laboratory of Biological Psychiatry","award":["ZDSYS2020004"],"award-info":[{"award-number":["ZDSYS2020004"]}]},{"name":"the College Students\u2032 Innovation and Entrepreneurship Training Programs of Henan Province","award":["202410472003"],"award-info":[{"award-number":["202410472003"]}]},{"DOI":"10.13039\/501100013254","name":"National College Students Innovation and Entrepreneurship Training Program","doi-asserted-by":"publisher","award":["202510472014"],"award-info":[{"award-number":["202510472014"]}],"id":[{"id":"10.13039\/501100013254","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Xinxiang Medical College Doctoral Start-up Fund","award":["505505"],"award-info":[{"award-number":["505505"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00415-025-13456-8","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T17:44:52Z","timestamp":1760723092000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Advances of therapeutic strategies for Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"272","author":[{"given":"Xing","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruizhu","family":"Yue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwu","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenqiang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2068-8060","authenticated-orcid":false,"given":"Linlin","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaokun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"8","key":"13456_CR1","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR et al (2024) Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement 20(8):5143\u20135169. https:\/\/doi.org\/10.1002\/alz.13859","journal-title":"Alzheimers Dement"},{"issue":"3","key":"13456_CR2","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1002\/alz.12730","volume":"19","author":"J-T Wang","year":"2023","unstructured":"Wang J-T et al (2023) The impacts of health insurance and resource on the burden of Alzheimer\u2019s disease and related dementias in the world population. Alzheimers Dement 19(3):967\u2013979","journal-title":"Alzheimers Dement"},{"issue":"10284","key":"13456_CR3","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P et al (2021) Alzheimer\u2019s disease. Lancet 397(10284):1577\u20131590","journal-title":"Lancet"},{"issue":"6","key":"13456_CR4","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ca.980080612","volume":"8","author":"RA Stelzmann","year":"2005","unstructured":"Stelzmann RA et al (2005) An english translation of Alzheimer\u2019s 1907 paper, \u201c\u00fcber eine eigenartige erkankung der hirnrinde.\u201d Clin Anat 8(6):429\u2013431. https:\/\/doi.org\/10.1002\/ca.980080612","journal-title":"Clin Anat"},{"issue":"12","key":"13456_CR5","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1007\/s11427-022-2357-x","volume":"66","author":"X Li","year":"2023","unstructured":"Li X et al (2023) Critical thinking of Alzheimer\u2019s transgenic mouse model: current research and future perspective. Sci China Life Sci 66(12):2711\u20132754. https:\/\/doi.org\/10.1007\/s11427-022-2357-x","journal-title":"Sci China Life Sci"},{"issue":"1","key":"13456_CR6","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s40035-024-00432-x","volume":"13","author":"E Liu","year":"2024","unstructured":"Liu E et al (2024) Updates in Alzheimer\u2019s disease: from basic research to diagnosis and therapies. Transl Neurodegener 13(1):45. https:\/\/doi.org\/10.1186\/s40035-024-00432-x","journal-title":"Transl Neurodegener"},{"issue":"1","key":"13456_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-024-00434-9","volume":"13","author":"N Liu","year":"2024","unstructured":"Liu N et al (2024) Trajectory of brain-derived amyloid beta in Alzheimer\u2019s disease: where is it coming from and where is it going? Transl Neurodegener 13(1):42. https:\/\/doi.org\/10.1186\/s40035-024-00434-9","journal-title":"Transl Neurodegener"},{"issue":"1","key":"13456_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-024-00429-6","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X et al (2024) Tau in neurodegenerative diseases: molecular mechanisms, biomarkers, and therapeutic strategies. Transl Neurodegener 13(1):40. https:\/\/doi.org\/10.1186\/s40035-024-00429-6","journal-title":"Transl Neurodegener"},{"issue":"3","key":"13456_CR9","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1007\/s12035-024-04449-1","volume":"62","author":"L Qu","year":"2024","unstructured":"Qu L et al (2024) Apolipoprotein E in Alzheimer\u2019s disease: focus on synaptic function and therapeutic strategy. Mol Neurobiol 62(3):3040\u20133052. https:\/\/doi.org\/10.1007\/s12035-024-04449-1","journal-title":"Mol Neurobiol"},{"issue":"1","key":"13456_CR10","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s00401-024-02790-2","volume":"148","author":"P BotellaLucena","year":"2024","unstructured":"BotellaLucena P, Heneka MT (2024) Inflammatory aspects of Alzheimer\u2019s disease. Acta Neuropathol 148(1):31. https:\/\/doi.org\/10.1007\/s00401-024-02790-2","journal-title":"Acta Neuropathol"},{"key":"13456_CR11","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.neuroscience.2024.08.008","volume":"557","author":"J Chen","year":"2024","unstructured":"Chen J et al (2024) Alzheimer\u2019s disease and sleep disorders: a bidirectional relationship. Neuroscience 557:12\u201323. https:\/\/doi.org\/10.1016\/j.neuroscience.2024.08.008","journal-title":"Neuroscience"},{"key":"13456_CR12","doi-asserted-by":"publisher","unstructured":"Allsop D, Hardy J (1991) Amyloici deposition as the central event in the aetiology of Alzheimer\u2019s disease. Trends Pharmacol Sci 12(10):383\u2013388. https:\/\/doi.org\/10.1016\/0165-6147(91)90609-v.","DOI":"10.1016\/0165-6147(91)90609-v"},{"issue":"5054","key":"13456_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1126\/science.1566067","volume":"256","author":"JAHaGA Higgins","year":"1992","unstructured":"Higgins JAHaGA (1992) Alzheimer\u2019s disease: the amyloid cascade hypothesis. Science 256(5054):184\u2013185. https:\/\/doi.org\/10.1126\/science.1566067","journal-title":"Science"},{"key":"13456_CR14","doi-asserted-by":"publisher","unstructured":"Vassar R, et al (1999) \u03b2-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286 (5440):735\u2013741.https:\/\/doi.org\/10.1126\/science.286.5440.735","DOI":"10.1126\/science.286.5440.735"},{"key":"13456_CR15","doi-asserted-by":"publisher","unstructured":"Chen J, et al (2024) Amyloid precursor protein: a regulatory hub in Alzheimer\u2019s disease. Aging Dis 15 (1): 201\u2013225. https:\/\/doi.org\/10.14336\/ad.2023.0308","DOI":"10.14336\/ad.2023.0308"},{"issue":"37","key":"13456_CR16","doi-asserted-by":"publisher","DOI":"10.1523\/jneurosci.0675-24.2024","volume":"44","author":"O Prikhodko","year":"2024","unstructured":"Prikhodko O et al (2024) Amyloid-\u03b2 causes NMDA receptor dysfunction and dendritic spine loss through mGluR1 and AKAP150-anchored calcineurin signaling. J Neurosci 44(37):e0675242024. https:\/\/doi.org\/10.1523\/jneurosci.0675-24.2024","journal-title":"J Neurosci"},{"issue":"13","key":"13456_CR17","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.neuron.2023.04.007","volume":"111","author":"AM Stern","year":"2023","unstructured":"Stern AM et al (2023) Abundant A\u03b2 fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer\u2019s disease brains. Neuron 111(13):2012\u20132020. https:\/\/doi.org\/10.1016\/j.neuron.2023.04.007","journal-title":"Neuron"},{"issue":"11","key":"13456_CR18","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1039\/c9cc09233a","volume":"56","author":"G Lv","year":"2020","unstructured":"Lv G et al (2020) A novel near-infrared fluorescent probe for detection of early stage A\u03b2 protofibrils in Alzheimer\u2019s disease. Chem Commun (Camb) 56(11):1625\u20131628. https:\/\/doi.org\/10.1039\/c9cc09233a","journal-title":"Chem Commun (Camb)"},{"key":"13456_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107514","volume":"150","author":"X Zhao","year":"2024","unstructured":"Zhao X et al (2024) Design and synthesis of hemicyanine-based NIRF probe for detecting A\u03b2 aggregates in Alzheimer\u2019s disease. Bioorg Chem 150:107514. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107514","journal-title":"Bioorg Chem"},{"issue":"12","key":"13456_CR20","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1038\/s41593-023-01484-4","volume":"26","author":"M Zielinski","year":"2023","unstructured":"Zielinski M et al (2023) Cryo-EM of A\u03b2 fibrils from mouse models find tg-APP(ArcSwe) fibrils resemble those found in patients with sporadic Alzheimer\u2019s disease. Nat Neurosci 26(12):2073\u20132080. https:\/\/doi.org\/10.1038\/s41593-023-01484-4","journal-title":"Nat Neurosci"},{"issue":"4","key":"13456_CR21","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1021\/jacs.2c09231","volume":"145","author":"N Becker","year":"2023","unstructured":"Becker N et al (2023) Atomic resolution insights into pH shift induced deprotonation events in LS-shaped A\u03b2(1\u201342) amyloid fibrils. J Am Chem Soc 145(4):2161\u20132169. https:\/\/doi.org\/10.1021\/jacs.2c09231","journal-title":"J Am Chem Soc"},{"issue":"41","key":"13456_CR22","doi-asserted-by":"publisher","first-page":"8461","DOI":"10.1523\/jneurosci.0494-21.2021","volume":"41","author":"M Wu","year":"2021","unstructured":"Wu M et al (2021) Unbalanced regulation of \u03b17 nAChRs by Ly6h and NACHO contributes to neurotoxicity in Alzheimer\u2019s disease. J Neurosci 41(41):8461\u20138474. https:\/\/doi.org\/10.1523\/jneurosci.0494-21.2021","journal-title":"J Neurosci"},{"key":"13456_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174310","volume":"908","author":"P Babaei","year":"2021","unstructured":"Babaei P (2021) NMDA and AMPA receptors dysregulation in Alzheimer\u2019s disease. Eur J Pharmacol 908:174310. https:\/\/doi.org\/10.1016\/j.ejphar.2021.174310","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"13456_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-025-00796-2","volume":"20","author":"J Ye","year":"2025","unstructured":"Ye J et al (2025) Upregulated astrocyte HDAC7 induces Alzheimer-like tau pathologies via deacetylating transcription factor-EB and inhibiting lysosome biogenesis. Mol Neurodegener 20(1):5. https:\/\/doi.org\/10.1186\/s13024-025-00796-2","journal-title":"Mol Neurodegener"},{"issue":"1","key":"13456_CR25","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s42003-024-06832-z","volume":"7","author":"A Cheng","year":"2024","unstructured":"Cheng A et al (2024) S-Nitrosylation of p39 promotes its degradation and contributes to synaptic dysfunction induced by \u03b2-amyloid peptide. Commun Biol 7(1):1113. https:\/\/doi.org\/10.1038\/s42003-024-06832-z","journal-title":"Commun Biol"},{"issue":"9","key":"13456_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0289435","volume":"19","author":"M Parvand","year":"2024","unstructured":"Parvand M et al (2024) A familial Alzheimer\u2019s disease associated mutation in presenilin-1 mediates amyloid-beta independent cell specific neurodegeneration. PLoS ONE 19(9):e0289435. https:\/\/doi.org\/10.1371\/journal.pone.0289435","journal-title":"PLoS ONE"},{"key":"13456_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1326-1-5","volume":"1","author":"H Zheng","year":"2006","unstructured":"Zheng H, Koo EH (2006) The amyloid precursor protein: beyond amyloid. Mol Neurodegener 1:5. https:\/\/doi.org\/10.1186\/1750-1326-1-5","journal-title":"Mol Neurodegener"},{"issue":"1","key":"13456_CR28","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13024-025-00878-1","volume":"20","author":"L de Weerd","year":"2025","unstructured":"de Weerd L et al (2025) Early intervention anti-A\u03b2 immunotherapy attenuates microglial activation without inducing exhaustion at residual plaques. Mol Neurodegener 20(1):92. https:\/\/doi.org\/10.1186\/s13024-025-00878-1","journal-title":"Mol Neurodegener"},{"issue":"7","key":"13456_CR29","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1016\/j.apsb.2024.03.034","volume":"14","author":"A Barrera-Ocampo","year":"2024","unstructured":"Barrera-Ocampo A (2024) Monoclonal antibodies and aptamers: the future therapeutics for Alzheimer\u2019s disease. Acta Pharm Sin B 14(7):2795\u20132814. https:\/\/doi.org\/10.1016\/j.apsb.2024.03.034","journal-title":"Acta Pharm Sin B"},{"issue":"6740","key":"13456_CR30","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/22124","volume":"400","author":"D Schenk","year":"1999","unstructured":"Schenk D et al (1999) Immunization with amyloid-\u03b2 attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400(6740):173\u2013177. https:\/\/doi.org\/10.1038\/22124","journal-title":"Nature"},{"issue":"1","key":"13456_CR31","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1212\/01.wnl.0000073623.84147.a8","volume":"61","author":"JM Orgogozo","year":"2003","unstructured":"Orgogozo JM et al (2003) Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61(1):46\u201354. https:\/\/doi.org\/10.1212\/01.wnl.0000073623.84147.a8","journal-title":"Neurology"},{"issue":"4","key":"13456_CR32","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s13139-024-00848-3","volume":"58","author":"KW Park","year":"2024","unstructured":"Park KW (2024) Anti-amyloid antibody therapies for Alzheimer\u2019s disease. Nucl Med Mol Imaging 58(4):227\u2013236. https:\/\/doi.org\/10.1007\/s13139-024-00848-3","journal-title":"Nucl Med Mol Imaging"},{"issue":"4","key":"13456_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS et al (2018) Trial of solanezumab for mild dementia due to Alzheimer\u2019s disease. N Engl J Med 378(4):321\u2013330","journal-title":"N Engl J Med"},{"issue":"11","key":"13456_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13113098","volume":"13","author":"G Tondo","year":"2024","unstructured":"Tondo G et al (2024) Novel therapeutic strategies in Alzheimer\u2019s disease: pitfalls and challenges of anti-amyloid therapies and beyond. J Clin Med 13(11):3098. https:\/\/doi.org\/10.3390\/jcm13113098","journal-title":"J Clin Med"},{"issue":"8","key":"13456_CR35","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/78682","volume":"6","author":"F Bard","year":"2000","unstructured":"Bard F et al (2000) Peripherally administered antibodies against amyloid \u03b2-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8):916\u2013919. https:\/\/doi.org\/10.1038\/78682","journal-title":"Nat Med"},{"issue":"6","key":"13456_CR36","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1007\/s40120-023-00541-1","volume":"12","author":"A Esquer","year":"2023","unstructured":"Esquer A et al (2023) Immunotherapies targeting amyloid and tau protein in Alzheimer\u2019s disease: should we move away from diseases and focus on biological targets? a systematic review and expert opinion. Neurol Ther 12(6):1883\u20131907. https:\/\/doi.org\/10.1007\/s40120-023-00541-1","journal-title":"Neurol Ther"},{"issue":"7","key":"13456_CR37","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway S et al (2021) A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat Med 27(7):1187\u20131196. https:\/\/doi.org\/10.1038\/s41591-021-01369-8","journal-title":"Nat Med"},{"issue":"7618","key":"13456_CR38","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature19323","volume":"537","author":"J Sevigny","year":"2016","unstructured":"Sevigny J et al (2016) The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease. Nature 537(7618):50\u201356. https:\/\/doi.org\/10.1038\/nature19323","journal-title":"Nature"},{"issue":"2","key":"13456_CR39","doi-asserted-by":"publisher","first-page":"197","DOI":"10.14283\/jpad.2022.30","volume":"9","author":"S Budd Haeberlein","year":"2022","unstructured":"Budd Haeberlein S et al (2022) Two randomized phase 3 studies of aducanumab in early Alzheimer\u2019s disease. J Prev Alzheimers Dis 9(2):197\u2013210. https:\/\/doi.org\/10.14283\/jpad.2022.30","journal-title":"J Prev Alzheimers Dis"},{"issue":"Sp. 1","key":"13456_CR40","doi-asserted-by":"publisher","first-page":"42","DOI":"10.7705\/biomedica.6967","volume":"44","author":"A Torres","year":"2024","unstructured":"Torres A et al (2024) Aducanumab: una mirada dos a\u00f1os despu\u00e9s de su aprobaci\u00f3n. Biomedica 44(Sp. 1):42\u201346. https:\/\/doi.org\/10.7705\/biomedica.6967","journal-title":"Biomedica"},{"issue":"9","key":"13456_CR41","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1056\/NEJMp2111320","volume":"385","author":"GD Rabinovici","year":"2021","unstructured":"Rabinovici GD (2021) Controversy and progress in Alzheimer\u2019s disease\u2014FDA approval of aducanumab. N Engl J Med 385(9):771\u2013774. https:\/\/doi.org\/10.1056\/NEJMp2111320","journal-title":"N Engl J Med"},{"issue":"45","key":"13456_CR42","doi-asserted-by":"publisher","first-page":"38825","DOI":"10.1074\/jbc.R111.288308","volume":"286","author":"S Jawhar","year":"2011","unstructured":"Jawhar S et al (2011) Pyroglutamate amyloid-\u03b2 (A\u03b2): a hatchet man in Alzheimer disease*. J Biol Chem 286(45):38825\u201338832","journal-title":"J Biol Chem"},{"issue":"1","key":"13456_CR43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","volume":"79","author":"S Salloway","year":"2022","unstructured":"Salloway S et al (2022) Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 79(1):13\u201321. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4161","journal-title":"JAMA Neurol"},{"issue":"6","key":"13456_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70224","volume":"21","author":"J Cummings","year":"2025","unstructured":"Cummings J et al (2025) Evaluation of cognitive, functional, and behavioral effects observed in EMERGE, a phase 3 trial of aducanumab in people with early Alzheimer\u2019s disease. Alzheimers Dement 21(6):e70224. https:\/\/doi.org\/10.1002\/alz.70224","journal-title":"Alzheimers Dement"},{"issue":"3","key":"13456_CR45","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70045","volume":"21","author":"V Devanarayan","year":"2025","unstructured":"Devanarayan V et al (2025) Predicted natural progression as an Alzheimer\u2019s prognostic covariate improves the precision of lecanemab efficacy assessments and clinical trial efficiency. Alzheimers Dement 21(3):e70045. https:\/\/doi.org\/10.1002\/alz.70045","journal-title":"Alzheimers Dement"},{"issue":"1","key":"13456_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH et al (2023) Lecanemab in early Alzheimer\u2019s disease. N Engl J Med 388(1):9\u201321. https:\/\/doi.org\/10.1056\/NEJMoa2212948","journal-title":"N Engl J Med"},{"issue":"5","key":"13456_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70293","volume":"21","author":"S Salloway","year":"2025","unstructured":"Salloway S et al (2025) Trailblazer-alz 4: a phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer\u2019s disease. Alzheimers Dement 21(5):e70293. https:\/\/doi.org\/10.1002\/alz.70293","journal-title":"Alzheimers Dement"},{"key":"13456_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102203","volume":"94","author":"I Terao","year":"2024","unstructured":"Terao I, Kodama W (2024) Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer\u2019s disease: a systematic review and network meta-analysis. Ageing Res Rev 94:102203. https:\/\/doi.org\/10.1016\/j.arr.2024.102203","journal-title":"Ageing Res Rev"},{"issue":"5","key":"13456_CR49","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1001\/jama.2022.24490","volume":"329","author":"HD Larkin","year":"2023","unstructured":"Larkin HD (2023) Lecanemab gains FDA approval for early Alzheimer disease. JAMA 329(5):363. https:\/\/doi.org\/10.1001\/jama.2022.24490","journal-title":"JAMA"},{"key":"13456_CR50","doi-asserted-by":"publisher","unstructured":"Dyer O (2024) Donanemab: FDA experts recommend approval of Alzheimer\u2019s drug. Bmj: q1327. https:\/\/doi.org\/10.1136\/bmj.q1327","DOI":"10.1136\/bmj.q1327"},{"issue":"7943","key":"13456_CR51","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/d41586-023-00030-3","volume":"613","author":"S Reardon","year":"2023","unstructured":"Reardon S (2023) FDA approves Alzheimer\u2019s drug lecanemab amid safety concerns. Nature 613(7943):227\u2013228. https:\/\/doi.org\/10.1038\/d41586-023-00030-3","journal-title":"Nature"},{"key":"13456_CR52","doi-asserted-by":"publisher","unstructured":"Lenzer J, Brownlee S (2024) Donanemab: conflicts of interest found in FDA committee that approved new Alzheimer\u2019s drug. Bmj: q2010. https:\/\/doi.org\/10.1136\/bmj.q2010","DOI":"10.1136\/bmj.q2010"},{"issue":"3","key":"13456_CR53","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41582-020-00454-9","volume":"17","author":"H Fillit","year":"2021","unstructured":"Fillit H, Green A (2021) Aducanumab and the FDA\u2014where are we now? Nat Rev Neurol 17(3):129\u2013130. https:\/\/doi.org\/10.1038\/s41582-020-00454-9","journal-title":"Nat Rev Neurol"},{"issue":"11","key":"13456_CR54","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-021-00557-x","volume":"17","author":"KY Liu","year":"2021","unstructured":"Liu KY, Howard R (2021) Can we learn lessons from the FDA\u2019s approval of aducanumab? Nat Rev Neurol 17(11):715\u2013722. https:\/\/doi.org\/10.1038\/s41582-021-00557-x","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"13456_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70086","volume":"21","author":"E Fertan","year":"2025","unstructured":"Fertan E et al (2025) Lecanemab preferentially binds to smaller aggregates present at early Alzheimer\u2019s disease. Alzheimers Dement 21(4):e70086. https:\/\/doi.org\/10.1002\/alz.70086","journal-title":"Alzheimers Dement"},{"issue":"17","key":"13456_CR56","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1056\/NEJMc2302856","volume":"388","author":"P-TT Bing-Syuan Zeng","year":"2023","unstructured":"Bing-Syuan Zeng P-TT, Liang C-S (2023) Lecanemab in early Alzheimer\u2019s Disease. N Engl J Med 388(17):1629\u20131630. https:\/\/doi.org\/10.1056\/NEJMc2302856","journal-title":"N Engl J Med"},{"issue":"10367","key":"13456_CR57","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1016\/s0140-6736(22)02480-1","volume":"400","author":"L The","year":"2022","unstructured":"The L (2022) Lecanemab for Alzheimer\u2019s disease: tempering hype and hope. The Lancet 400(10367):1899. https:\/\/doi.org\/10.1016\/s0140-6736(22)02480-1","journal-title":"The Lancet"},{"issue":"4","key":"13456_CR58","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1038\/s41380-021-01409-2","volume":"27","author":"TA Bayer","year":"2021","unstructured":"Bayer TA (2021) Pyroglutamate A\u03b2 cascade as drug target in Alzheimer\u2019s disease. Mol Psychiatry 27(4):1880\u20131885. https:\/\/doi.org\/10.1038\/s41380-021-01409-2","journal-title":"Mol Psychiatry"},{"issue":"20","key":"13456_CR59","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","volume":"186","author":"M Jucker","year":"2023","unstructured":"Jucker M, Walker LC (2023) Alzheimer\u2019s disease: from immunotherapy to immunoprevention. Cell 186(20):4260\u20134270. https:\/\/doi.org\/10.1016\/j.cell.2023.08.021","journal-title":"Cell"},{"issue":"4","key":"13456_CR60","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41582-024-01053-8","volume":"21","author":"SM Greenberg","year":"2025","unstructured":"Greenberg SM et al (2025) Amyloid-related imaging abnormalities: manifestations, metrics and mechanisms. Nat Rev Neurol 21(4):193\u2013203. https:\/\/doi.org\/10.1038\/s41582-024-01053-8","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"13456_CR61","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","volume":"79","author":"M Filippi","year":"2022","unstructured":"Filippi M et al (2022) Amyloid-related imaging abnormalities and \u03b2-amyloid-targeting antibodies. JAMA Neurol 79(3):291\u2013304. https:\/\/doi.org\/10.1001\/jamaneurol.2021.5205","journal-title":"JAMA Neurol"},{"issue":"4","key":"13456_CR62","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA et al (2011) Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer\u2019s Association Research Roundtable Workgroup. Alzheimers Dement 7(4):367\u2013385. https:\/\/doi.org\/10.1016\/j.jalz.2011.05.2351","journal-title":"Alzheimers Dement"},{"key":"13456_CR63","doi-asserted-by":"publisher","unstructured":"Black RS, Reisa A, Safirstein RA, Beth S, Motter RN, Pallay A, Nichols A, Grundman M (2010) A single ascending dose study of bapineuzumab in patients with Alzheimer disease. Alz Dis Assoc Dis 24(2): 198\u2013203. https:\/\/doi.org\/10.1097\/WAD.0b013e3181c53b00","DOI":"10.1097\/WAD.0b013e3181c53b00"},{"issue":"1","key":"13456_CR64","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.dadm.2016.02.004","volume":"2","author":"C Carlson","year":"2016","unstructured":"Carlson C et al (2016) Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer\u2019s disease. Alzheimer\u2019s Dementia: Diagnosis, Assessment & Disease Monitoring 2(1):75\u201385. https:\/\/doi.org\/10.1016\/j.dadm.2016.02.004","journal-title":"Alzheimer\u2019s Dementia: Diagnosis, Assessment & Disease Monitoring"},{"issue":"6","key":"13456_CR65","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1001\/jama.2023.13239","volume":"330","author":"JR Sims","year":"2023","unstructured":"Sims JR et al (2023) Donanemab in early symptomatic Alzheimer disease. JAMA 330(6):512\u2013527. https:\/\/doi.org\/10.1001\/jama.2023.13239","journal-title":"JAMA"},{"issue":"3","key":"13456_CR66","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/s1474-4422(12)70015-7","volume":"11","author":"R Sperling","year":"2012","unstructured":"Sperling R et al (2012) Amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol 11(3):241\u2013249. https:\/\/doi.org\/10.1016\/s1474-4422(12)70015-7","journal-title":"Lancet Neurol"},{"issue":"5","key":"13456_CR67","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000209582","volume":"103","author":"J Neves Briard","year":"2024","unstructured":"Neves Briard J et al (2024) Refractory status epilepticus in a patient with aducanumab-induced amyloid-related imaging abnormalities. Neurology 103(5):e209582. https:\/\/doi.org\/10.1212\/wnl.0000000000209582","journal-title":"Neurology"},{"issue":"2","key":"13456_CR68","doi-asserted-by":"publisher","first-page":"221","DOI":"10.14283\/jpad.2022.34","volume":"9","author":"J Cummings","year":"2022","unstructured":"Cummings J et al (2022) Aducanumab: appropriate use recommendations update. J Prev Alzheimers Dis 9(2):221\u2013230. https:\/\/doi.org\/10.14283\/jpad.2022.34","journal-title":"J Prev Alzheimers Dis"},{"issue":"11","key":"13456_CR69","doi-asserted-by":"publisher","first-page":"8162","DOI":"10.1002\/alz.14199","volume":"20","author":"DM Rentz","year":"2024","unstructured":"Rentz DM et al (2024) Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer\u2019s disease: navigating clinician-patient engagement. Alzheimers Dement 20(11):8162\u20138171. https:\/\/doi.org\/10.1002\/alz.14199","journal-title":"Alzheimers Dement"},{"issue":"20","key":"13456_CR70","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1056\/NEJMoa2304430","volume":"389","author":"RJ Bateman","year":"2023","unstructured":"Bateman RJ et al (2023) Two phase 3 trials of Gantenerumab in early Alzheimer\u2019s disease. N Engl J Med 389(20):1862\u20131876. https:\/\/doi.org\/10.1056\/NEJMoa2304430","journal-title":"N Engl J Med"},{"key":"13456_CR71","doi-asserted-by":"publisher","unstructured":"Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, Petersen RC, Trojanowski JQ (2010) Hypothetical model of dynamic biomarkers of the Alzheimer\u2019s pathological cascade. Lancet Neurol 9(1): 119\u2013128. https:\/\/doi.org\/10.1016\/S1474-4422(09)70299-6","DOI":"10.1016\/S1474-4422(09)70299-6"},{"issue":"15","key":"13456_CR72","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1001\/jama.2024.13855","volume":"332","author":"S Palmqvist","year":"2024","unstructured":"Palmqvist S et al (2024) Blood biomarkers to detect Alzheimer disease in primary care and secondary care. JAMA 332(15):1245\u20131257. https:\/\/doi.org\/10.1001\/jama.2024.13855","journal-title":"JAMA"},{"issue":"9","key":"13456_CR73","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jamaneurol.2024.2619","volume":"81","author":"S Janelidze","year":"2024","unstructured":"Janelidze S et al (2024) Plasma phosphorylated tau 217 and A\u03b242\/40 to predict early brain A\u03b2 accumulation in people without cognitive impairment. JAMA Neurol 81(9):947\u2013957. https:\/\/doi.org\/10.1001\/jamaneurol.2024.2619","journal-title":"JAMA Neurol"},{"issue":"5","key":"13456_CR74","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1001\/jamaneurol.2022.0315","volume":"79","author":"EL Ross","year":"2022","unstructured":"Ross EL et al (2022) Cost-effectiveness of aducanumab and donanemab for early Alzheimer disease in the US. JAMA Neurol 79(5):478\u2013487. https:\/\/doi.org\/10.1001\/jamaneurol.2022.0315","journal-title":"JAMA Neurol"},{"issue":"7","key":"13456_CR75","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000209218","volume":"102","author":"HV Nguyen","year":"2024","unstructured":"Nguyen HV et al (2024) Cost-effectiveness of lecanemab for individuals with early-stage Alzheimer disease. Neurology 102(7):e209218. https:\/\/doi.org\/10.1212\/wnl.0000000000209218","journal-title":"Neurology"},{"issue":"12","key":"13456_CR76","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/s41582-023-00883-2","volume":"19","author":"EE Congdon","year":"2023","unstructured":"Congdon EE et al (2023) Tau-targeting therapies for Alzheimer disease: current status and future directions. Nat Rev Neurol 19(12):715\u2013736. https:\/\/doi.org\/10.1038\/s41582-023-00883-2","journal-title":"Nat Rev Neurol"},{"issue":"2","key":"13456_CR77","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1152\/physrev.00024.2003","volume":"84","author":"J Avila","year":"2004","unstructured":"Avila J et al (2004) Role of tau protein in both physiological and pathological conditions. Physiol Rev 84(2):361\u2013384. https:\/\/doi.org\/10.1152\/physrev.00024.2003","journal-title":"Physiol Rev"},{"issue":"7","key":"13456_CR78","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.4103\/1673-5374.385847","volume":"19","author":"J Ye","year":"2024","unstructured":"Ye J et al (2024) Targeting tau in Alzheimer\u2019s disease: from mechanisms to clinical therapy. Neural Regen Res 19(7):1489\u20131498. https:\/\/doi.org\/10.4103\/1673-5374.385847","journal-title":"Neural Regen Res"},{"issue":"1","key":"13456_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-021-00460-5","volume":"16","author":"Y Xia","year":"2021","unstructured":"Xia Y et al (2021) \u201cDon\u2019t Phos Over Tau\u201d: recent developments in clinical biomarkers and therapies targeting tau phosphorylation in Alzheimer\u2019s disease and other tauopathies. Mol Neurodegener 16(1):37. https:\/\/doi.org\/10.1186\/s13024-021-00460-5","journal-title":"Mol Neurodegener"},{"issue":"6","key":"13456_CR80","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.neuron.2010.11.030","volume":"68","author":"BR Hoover","year":"2010","unstructured":"Hoover BR et al (2010) Tau mislocalization to dendritic spines mediates synaptic dysfunction independently of neurodegeneration. Neuron 68(6):1067\u20131081","journal-title":"Neuron"},{"issue":"6","key":"13456_CR81","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nsmb.2555","volume":"20","author":"TJ Cohen","year":"2013","unstructured":"Cohen TJ et al (2013) The microtubule-associated tau protein has intrinsic acetyltransferase activity. Nat Struct Mol Biol 20(6):756\u2013762. https:\/\/doi.org\/10.1038\/nsmb.2555","journal-title":"Nat Struct Mol Biol"},{"issue":"6","key":"13456_CR82","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.neuron.2010.08.044","volume":"67","author":"SW Min","year":"2010","unstructured":"Min SW et al (2010) Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 67(6):953\u2013966. https:\/\/doi.org\/10.1016\/j.neuron.2010.08.044","journal-title":"Neuron"},{"key":"13456_CR83","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms1255","volume":"2","author":"TJ Cohen","year":"2011","unstructured":"Cohen TJ et al (2011) The acetylation of tau inhibits its function and promotes pathological tau aggregation. Nat Commun 2:252. https:\/\/doi.org\/10.1038\/ncomms1255","journal-title":"Nat Commun"},{"issue":"2","key":"13456_CR84","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1021\/acschemneuro.8b00457","volume":"10","author":"D Chu","year":"2018","unstructured":"Chu D, Liu F (2018) Pathological changes of tau related to Alzheimer\u2019s disease. ACS Chem Neurosci 10(2):931\u2013944. https:\/\/doi.org\/10.1021\/acschemneuro.8b00457","journal-title":"ACS Chem Neurosci"},{"issue":"1","key":"13456_CR85","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1093\/hmg\/ddt402","volume":"23","author":"C Cook","year":"2014","unstructured":"Cook C et al (2014) Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance. Hum Mol Genet 23(1):104\u2013116. https:\/\/doi.org\/10.1093\/hmg\/ddt402","journal-title":"Hum Mol Genet"},{"issue":"1","key":"13456_CR86","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3233\/JAD-170959","volume":"63","author":"JP Quinn","year":"2018","unstructured":"Quinn JP et al (2018) Tau proteolysis in the pathogenesis of tauopathies: neurotoxic fragments and novel biomarkers. J Alzheimers Dis 63(1):13\u201333. https:\/\/doi.org\/10.3233\/JAD-170959","journal-title":"J Alzheimers Dis"},{"key":"13456_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.595532","volume":"11","author":"C Alquezar","year":"2020","unstructured":"Alquezar C et al (2020) Tau Post-translational modifications: dynamic transformers of tau function, degradation, and aggregation. Front Neurol 11:595532. https:\/\/doi.org\/10.3389\/fneur.2020.595532","journal-title":"Front Neurol"},{"key":"13456_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2021.661368","volume":"14","author":"FX Cantrelle","year":"2021","unstructured":"Cantrelle FX et al (2021) Phosphorylation and O-GlcNAcylation of the PHF-1 epitope of Tau protein induce local conformational changes of the C-terminus and modulate Tau self-assembly into fibrillar aggregates. Front Mol Neurosci 14:661368. https:\/\/doi.org\/10.3389\/fnmol.2021.661368","journal-title":"Front Mol Neurosci"},{"issue":"6","key":"13456_CR89","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1080\/00207454.2022.2130297","volume":"134","author":"DS Mandlik","year":"2024","unstructured":"Mandlik DS et al (2024) Therapeutic implications of glycogen synthase kinase-3\u03b2 in Alzheimer\u2019s disease: a novel therapeutic target. Int J Neurosci 134(6):603\u2013619. https:\/\/doi.org\/10.1080\/00207454.2022.2130297","journal-title":"Int J Neurosci"},{"issue":"1","key":"13456_CR90","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1096\/fj.12-217497","volume":"27","author":"V Shukla","year":"2013","unstructured":"Shukla V et al (2013) A truncated peptide from p35, a Cdk5 activator, prevents Alzheimer\u2019s disease phenotypes in model mice. FASEB j 27(1):174\u2013186. https:\/\/doi.org\/10.1096\/fj.12-217497","journal-title":"FASEB j"},{"issue":"5","key":"13456_CR91","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s00401-017-1707-9","volume":"133","author":"T Guo","year":"2017","unstructured":"Guo T et al (2017) Roles of tau protein in health and disease. Acta Neuropathol 133(5):665\u2013704. https:\/\/doi.org\/10.1007\/s00401-017-1707-9","journal-title":"Acta Neuropathol"},{"key":"13456_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2024.107811","volume":"153","author":"S Sukanya","year":"2024","unstructured":"Sukanya S et al (2024) Design, synthesis, and biological evaluation of tetrahydropyrimidine analogue as GSK-3\u03b2\/A\u03b2 aggregation inhibitor and anti-Alzheimer\u2019s agent. Bioorg Chem 153:107811. https:\/\/doi.org\/10.1016\/j.bioorg.2024.107811","journal-title":"Bioorg Chem"},{"key":"13456_CR93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176760","volume":"978","author":"S Garemilla","year":"2024","unstructured":"Garemilla S et al (2024) CDK5 as a therapeutic tool for the treatment of Alzheimer\u2019s disease: a review. Eur J Pharmacol 978:176760. https:\/\/doi.org\/10.1016\/j.ejphar.2024.176760","journal-title":"Eur J Pharmacol"},{"key":"13456_CR94","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3233\/JAD-151208","volume":"55","author":"RHLH Rueli","year":"2017","unstructured":"Rueli RHLH et al (2017) Selenoprotein s reduces endoplasmic reticulum stress-induced phosphorylation of Tau: potential role in selenate mitigation of tau pathology. J Alzheimers Dis 55:749\u2013762. https:\/\/doi.org\/10.3233\/JAD-151208","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"13456_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12299","volume":"8","author":"L Vivash","year":"2022","unstructured":"Vivash L et al (2022) A phase 1b open-label study of sodium selenate as a disease-modifying treatment for possible behavioral variant frontotemporal dementia. Alzheimers Dement (N Y) 8(1):e12299. https:\/\/doi.org\/10.1002\/trc2.12299","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"13456_CR96","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","volume":"35","author":"L Seren\u00f3","year":"2009","unstructured":"Seren\u00f3 L et al (2009) A novel GSK-3beta inhibitor reduces Alzheimer\u2019s pathology and rescues neuronal loss in vivo. Neurobiol Dis 35(3):359\u2013367. https:\/\/doi.org\/10.1016\/j.nbd.2009.05.025","journal-title":"Neurobiol Dis"},{"issue":"1","key":"13456_CR97","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3233\/jad-141959","volume":"45","author":"S Lovestone","year":"2015","unstructured":"Lovestone S et al (2015) A phase II trial of tideglusib in Alzheimer\u2019s disease. J Alzheimers Dis 45(1):75\u201388. https:\/\/doi.org\/10.3233\/jad-141959","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"13456_CR98","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1016\/j.cell.2021.03.032","volume":"184","author":"MK Shin","year":"2021","unstructured":"Shin MK et al (2021) Reducing acetylated tau is neuroprotective in brain injury. Cell 184(10):2715\u20132732. https:\/\/doi.org\/10.1016\/j.cell.2021.03.032","journal-title":"Cell"},{"issue":"10","key":"13456_CR99","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1038\/nm.3951","volume":"21","author":"SW Min","year":"2015","unstructured":"Min SW et al (2015) Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 21(10):1154\u20131162. https:\/\/doi.org\/10.1038\/nm.3951","journal-title":"Nat Med"},{"key":"13456_CR100","unstructured":"Alzforum (2022) Therapeutics: LY3372689. Alzforum. https:\/\/www.alzforum.org\/therapeutics\/ly3372689"},{"issue":"7","key":"13456_CR101","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1055\/a-2238-1384","volume":"56","author":"A Singh","year":"2024","unstructured":"Singh A et al (2024) Targeting abnormal tau phosphorylation for Alzheimer\u2019s therapeutics. Horm Metab Res 56(7):482\u2013488. https:\/\/doi.org\/10.1055\/a-2238-1384","journal-title":"Horm Metab Res"},{"key":"13456_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104707","volume":"134","author":"A Bittar","year":"2020","unstructured":"Bittar A et al (2020) Advances and considerations in AD tau-targeted immunotherapy. Neurobiol Dis 134:104707. https:\/\/doi.org\/10.1016\/j.nbd.2019.104707","journal-title":"Neurobiol Dis"},{"key":"13456_CR103","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.semcdb.2021.12.002","volume":"126","author":"EE Congdon","year":"2022","unstructured":"Congdon EE et al (2022) Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly. Semin Cell Dev Biol 126:125\u2013137. https:\/\/doi.org\/10.1016\/j.semcdb.2021.12.002","journal-title":"Semin Cell Dev Biol"},{"issue":"Pt B","key":"13456_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109445","volume":"113","author":"N Karimi","year":"2022","unstructured":"Karimi N et al (2022) Tau immunotherapy in Alzheimer\u2019s disease and progressive supranuclear palsy. Int Immunopharmacol 113(Pt B):109445. https:\/\/doi.org\/10.1016\/j.intimp.2022.109445","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"13456_CR105","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/s1474-4422(16)30331-3","volume":"16","author":"P Novak","year":"2017","unstructured":"Novak P et al (2017) Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 16(2):123\u2013134. https:\/\/doi.org\/10.1016\/s1474-4422(16)30331-3","journal-title":"Lancet Neurol"},{"issue":"6","key":"13456_CR106","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","volume":"1","author":"P Novak","year":"2021","unstructured":"Novak P et al (2021) ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease. Nat Aging 1(6):521\u2013534. https:\/\/doi.org\/10.1038\/s43587-021-00070-2","journal-title":"Nat Aging"},{"issue":"16","key":"13456_CR107","doi-asserted-by":"publisher","first-page":"13966","DOI":"10.1074\/jbc.M110.186338","volume":"286","author":"DT Hickman","year":"2011","unstructured":"Hickman DT et al (2011) Sequence-independent control of peptide conformation in liposomal vaccines for targeting protein misfolding diseases. J Biol Chem 286(16):13966\u201313976. https:\/\/doi.org\/10.1074\/jbc.M110.186338","journal-title":"J Biol Chem"},{"issue":"7","key":"13456_CR108","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/13543784.2023.2233892","volume":"32","author":"F Panza","year":"2023","unstructured":"Panza F et al (2023) Clinical development of passive tau-based immunotherapeutics for treating primary and secondary tauopathies. Expert Opin Investig Drugs 32(7):625\u2013634. https:\/\/doi.org\/10.1080\/13543784.2023.2233892","journal-title":"Expert Opin Investig Drugs"},{"issue":"1","key":"13456_CR109","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","volume":"8","author":"M Roberts","year":"2020","unstructured":"Roberts M et al (2020) Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer\u2019s disease. Acta Neuropathol Commun 8(1):13. https:\/\/doi.org\/10.1186\/s40478-020-0884-2","journal-title":"Acta Neuropathol Commun"},{"issue":"5123","key":"13456_CR110","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1126\/science.8346443","volume":"261","author":"EH Corder","year":"1993","unstructured":"Corder EH et al (1993) Gene dose of Apolipoprotein E type 4 allele and the risk of Alzheimer\u2019s disease in late onset families. Science 261(5123):921\u2013923","journal-title":"Science"},{"issue":"9","key":"13456_CR111","doi-asserted-by":"publisher","first-page":"6590","DOI":"10.1002\/alz.13877","volume":"20","author":"CM Kloske","year":"2024","unstructured":"Kloske CM et al (2024) Advancements in APOE and dementia research: highlights from the 2023 AAIC advancements: APOE conference. Alzheimers Dement 20(9):6590\u20136605. https:\/\/doi.org\/10.1002\/alz.13877","journal-title":"Alzheimers Dement"},{"issue":"2","key":"13456_CR112","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/nrneurol.2012.263","volume":"9","author":"C-C Liu","year":"2013","unstructured":"Liu C-C et al (2013) Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol 9(2):106\u2013118. https:\/\/doi.org\/10.1038\/nrneurol.2012.263","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"13456_CR113","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo A et al (2021) APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol 20(1):68\u201380. https:\/\/doi.org\/10.1016\/S1474-4422(20)30412-9","journal-title":"Lancet Neurol"},{"issue":"1","key":"13456_CR114","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1038\/s41467-021-23081-4","volume":"12","author":"J Zhao","year":"2021","unstructured":"Zhao J et al (2021) Author correction: APOE4 exacerbates synapse loss and neurodegeneration in Alzheimer\u2019s disease patient iPSC-derived cerebral organoids. Nat Commun 12(1):2707. https:\/\/doi.org\/10.1038\/s41467-021-23081-4","journal-title":"Nat Commun"},{"issue":"89","key":"13456_CR115","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano JM et al (2011) Human apoE isoforms differentially regulate brain amyloid-\u03b2 peptide clearance. Sci Transl Med 3(89):89ra57. https:\/\/doi.org\/10.1126\/scitranslmed.3002156","journal-title":"Sci Transl Med"},{"issue":"1","key":"13456_CR116","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1038\/s41598-019-40438-4","volume":"9","author":"A Mouchard","year":"2019","unstructured":"Mouchard A et al (2019) ApoE-fragment\/A\u03b2 heteromers in the brain of patients with Alzheimer\u2019s disease. Sci Rep 9(1):3989. https:\/\/doi.org\/10.1038\/s41598-019-40438-4","journal-title":"Sci Rep"},{"issue":"1","key":"13456_CR117","doi-asserted-by":"publisher","first-page":"3438","DOI":"10.1038\/s41598-021-82901-1","volume":"11","author":"AM Jablonski","year":"2021","unstructured":"Jablonski AM et al (2021) Astrocytic expression of the Alzheimer\u2019s disease risk allele, ApoE\u03b54, potentiates neuronal tau pathology in multiple preclinical models. Sci Rep 11(1):3438. https:\/\/doi.org\/10.1038\/s41598-021-82901-1","journal-title":"Sci Rep"},{"issue":"1","key":"13456_CR118","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-022-01006-x","volume":"7","author":"S Huang","year":"2022","unstructured":"Huang S et al (2022) Chimeric cerebral organoids reveal the essentials of neuronal and astrocytic APOE4 for Alzheimer\u2019s tau pathology. Signal Transduct Target Ther 7(1):176. https:\/\/doi.org\/10.1038\/s41392-022-01006-x","journal-title":"Signal Transduct Target Ther"},{"issue":"7673","key":"13456_CR119","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi Y et al (2017) ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549(7673):523\u2013527. https:\/\/doi.org\/10.1038\/nature24016","journal-title":"Nature"},{"issue":"4","key":"13456_CR120","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault J et al (2020) Association of apolipoprotein E \u03b54 with medial temporal tau independent of amyloid-\u03b2. JAMA Neurol 77(4):470\u2013479. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4421","journal-title":"JAMA Neurol"},{"issue":"12","key":"13456_CR121","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.1084\/jem.20121274","volume":"209","author":"J Kim","year":"2012","unstructured":"Kim J et al (2012) Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A\u03b2 amyloidosis. J Exp Med 209(12):2149\u20132156. https:\/\/doi.org\/10.1084\/jem.20121274","journal-title":"J Exp Med"},{"issue":"5","key":"13456_CR122","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","volume":"96","author":"CC Liu","year":"2017","unstructured":"Liu CC et al (2017) ApoE4 accelerates early seeding of amyloid pathology. Neuron 96(5):1024\u20131032. https:\/\/doi.org\/10.1016\/j.neuron.2017.11.013","journal-title":"Neuron"},{"issue":"4","key":"13456_CR123","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/ana.26864","volume":"95","author":"JM Vance","year":"2024","unstructured":"Vance JM et al (2024) Report of the APOE4 National institute on aging\/alzheimer disease sequencing project consortium working group: reducing APOE4 in carriers is a therapeutic goal for Alzheimer\u2019s disease. Ann Neurol 95(4):625\u2013634. https:\/\/doi.org\/10.1002\/ana.26864","journal-title":"Ann Neurol"},{"issue":"5","key":"13456_CR124","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1172\/jci96429","volume":"128","author":"F Liao","year":"2018","unstructured":"Liao F et al (2018) Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest 128(5):2144\u20132155. https:\/\/doi.org\/10.1172\/jci96429","journal-title":"J Clin Invest"},{"key":"13456_CR125","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd7522","author":"M Xiong","year":"2021","unstructured":"Xiong M et al (2021) Apoe immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.abd7522","journal-title":"Sci Transl Med"},{"issue":"2","key":"13456_CR126","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1002\/alz.13436","volume":"20","author":"C Marino","year":"2024","unstructured":"Marino C et al (2024) APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation. Alzheimers Dement 20(2):819\u2013836. https:\/\/doi.org\/10.1002\/alz.13436","journal-title":"Alzheimers Dement"},{"issue":"1","key":"13456_CR127","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00574-4","volume":"17","author":"AC Raulin","year":"2022","unstructured":"Raulin AC et al (2022) ApoE in Alzheimer\u2019s disease: pathophysiology and therapeutic strategies. Mol Neurodegener 17(1):72. https:\/\/doi.org\/10.1186\/s13024-022-00574-4","journal-title":"Mol Neurodegener"},{"issue":"5","key":"13456_CR128","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/ana.25455","volume":"85","author":"AR Wadhwani","year":"2019","unstructured":"Wadhwani AR et al (2019) Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in Alzheimer disease. Ann Neurol 85(5):726\u2013739. https:\/\/doi.org\/10.1002\/ana.25455","journal-title":"Ann Neurol"},{"issue":"6","key":"13456_CR129","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/j.neuron.2018.05.008","volume":"98","author":"YT Lin","year":"2018","unstructured":"Lin YT et al (2018) APOE4 causes widespread molecular and cellular alterations associated with Alzheimer\u2019s disease phenotypes in human iPSC-derived brain cell types. Neuron 98(6):1141\u20131154. https:\/\/doi.org\/10.1016\/j.neuron.2018.05.008","journal-title":"Neuron"},{"issue":"7","key":"13456_CR130","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14856","volume":"30","author":"M AmeliMojarad","year":"2024","unstructured":"AmeliMojarad M, AmeliMojarad M (2024) The neuroinflammatory role of microglia in Alzheimer\u2019s disease and their associated therapeutic targets. CNS Neurosci Ther 30(7):e14856. https:\/\/doi.org\/10.1111\/cns.14856","journal-title":"CNS Neurosci Ther"},{"issue":"1","key":"13456_CR131","doi-asserted-by":"publisher","first-page":"3417","DOI":"10.1038\/s41467-021-22491-8","volume":"12","author":"I de Rojas","year":"2021","unstructured":"de Rojas I et al (2021) Common variants in Alzheimer\u2019s disease and risk stratification by polygenic risk scores. Nat Commun 12(1):3417. https:\/\/doi.org\/10.1038\/s41467-021-22491-8","journal-title":"Nat Commun"},{"issue":"2","key":"13456_CR132","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1002\/alz.12389","volume":"18","author":"D Boche","year":"2022","unstructured":"Boche D, Gordon MN (2022) Diversity of transcriptomic microglial phenotypes in aging and Alzheimer\u2019s disease. Alzheimers Dement 18(2):360\u2013376. https:\/\/doi.org\/10.1002\/alz.12389","journal-title":"Alzheimers Dement"},{"issue":"12","key":"13456_CR133","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2174\/1570159x18666200529150907","volume":"18","author":"R Kang","year":"2020","unstructured":"Kang R et al (2020) The dual role of microglia in blood-brain barrier dysfunction after stroke. Curr Neuropharmacol 18(12):1237\u20131249. https:\/\/doi.org\/10.2174\/1570159x18666200529150907","journal-title":"Curr Neuropharmacol"},{"issue":"1","key":"13456_CR134","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00588-y","volume":"17","author":"J Hou","year":"2022","unstructured":"Hou J et al (2022) TREM2 dependent and independent functions of microglia in Alzheimer\u2019s disease. Mol Neurodegener 17(1):84. https:\/\/doi.org\/10.1186\/s13024-022-00588-y","journal-title":"Mol Neurodegener"},{"issue":"7","key":"13456_CR135","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","volume":"169","author":"H Keren-Shaul","year":"2017","unstructured":"Keren-Shaul H et al (2017) A unique microglia type associated with restricting development of Alzheimer\u2019s disease. Cell 169(7):1276\u20131290. https:\/\/doi.org\/10.1016\/j.cell.2017.05.018","journal-title":"Cell"},{"issue":"3","key":"13456_CR136","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","volume":"47","author":"S Krasemann","year":"2017","unstructured":"Krasemann S et al (2017) The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity 47(3):566\u2013581. https:\/\/doi.org\/10.1016\/j.immuni.2017.08.008","journal-title":"Immunity"},{"issue":"4","key":"13456_CR137","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.celrep.2019.03.099","volume":"27","author":"C Sala Frigerio","year":"2019","unstructured":"Sala Frigerio C et al (2019) The major risk factors for Alzheimer\u2019s disease: age, sex, and genes modulate the microglia response to A\u03b2 plaques. Cell Rep 27(4):1293\u20131306. https:\/\/doi.org\/10.1016\/j.celrep.2019.03.099","journal-title":"Cell Rep"},{"issue":"3","key":"13456_CR138","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201910606","volume":"12","author":"A Sierksma","year":"2020","unstructured":"Sierksma A et al (2020) Novel Alzheimer risk genes determine the microglia response to amyloid-\u03b2 but not to TAU pathology. EMBO Mol Med 12(3):e10606. https:\/\/doi.org\/10.15252\/emmm.201910606","journal-title":"EMBO Mol Med"},{"key":"13456_CR139","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2020.113506","volume":"336","author":"JB Ruganzu","year":"2021","unstructured":"Ruganzu JB et al (2021) TREM2 overexpression rescues cognitive deficits in APP\/PS1 transgenic mice by reducing neuroinflammation via the JAK\/STAT\/SOCS signaling pathway. Exp Neurol 336:113506. https:\/\/doi.org\/10.1016\/j.expneurol.2020.113506","journal-title":"Exp Neurol"},{"issue":"8","key":"13456_CR140","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/s41593-019-0433-0","volume":"22","author":"CEG Leyns","year":"2019","unstructured":"Leyns CEG et al (2019) TREM2 function impedes tau seeding in neuritic plaques. Nat Neurosci 22(8):1217\u20131222. https:\/\/doi.org\/10.1038\/s41593-019-0433-0","journal-title":"Nat Neurosci"},{"issue":"5","key":"13456_CR141","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1084\/jem.20151948","volume":"213","author":"Y Wang","year":"2016","unstructured":"Wang Y et al (2016) TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques. J Exp Med 213(5):667\u2013675. https:\/\/doi.org\/10.1084\/jem.20151948","journal-title":"J Exp Med"},{"issue":"4","key":"13456_CR142","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(22)00027-8","volume":"21","author":"E Morenas-Rodr\u00edguez","year":"2022","unstructured":"Morenas-Rodr\u00edguez E et al (2022) Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer\u2019s disease: a longitudinal observational study. Lancet Neurol 21(4):329\u2013341","journal-title":"Lancet Neurol"},{"issue":"17","key":"13456_CR143","doi-asserted-by":"publisher","first-page":"2920","DOI":"10.1093\/hmg\/ddaa179","volume":"29","author":"A Griciuc","year":"2020","unstructured":"Griciuc A et al (2020) Gene therapy for Alzheimer\u2019s disease targeting CD33 reduces amyloid beta accumulation and neuroinflammation. Hum Mol Genet 29(17):2920\u20132935. https:\/\/doi.org\/10.1093\/hmg\/ddaa179","journal-title":"Hum Mol Genet"},{"issue":"5","key":"13456_CR144","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.neuron.2019.06.010","volume":"103","author":"A Griciuc","year":"2019","unstructured":"Griciuc A et al (2019) TREM2 acts downstream of CD33 in modulating microglial pathology in Alzheimer\u2019s disease. Neuron 103(5):820\u2013835. https:\/\/doi.org\/10.1016\/j.neuron.2019.06.010","journal-title":"Neuron"},{"key":"13456_CR145","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106479","volume":"84","author":"MS Uddin","year":"2020","unstructured":"Uddin MS et al (2020) Pharmacological approaches to mitigate neuroinflammation in Alzheimer\u2019s disease. Int Immunopharmacol 84:106479. https:\/\/doi.org\/10.1016\/j.intimp.2020.106479","journal-title":"Int Immunopharmacol"},{"key":"13456_CR146","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2024.107404","author":"YG Fan","year":"2024","unstructured":"Fan YG et al (2024) Astrocyte-derived lactoferrin inhibits neuronal ferroptosis by reducing iron content and GPX4 degradation in APP\/PS1 transgenic mice. Pharmacol Res. https:\/\/doi.org\/10.1016\/j.phrs.2024.107404","journal-title":"Pharmacol Res"},{"issue":"2","key":"13456_CR147","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long JM, Holtzman DM (2019) Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179(2):312\u2013339. https:\/\/doi.org\/10.1016\/j.cell.2019.09.001","journal-title":"Cell"},{"issue":"3","key":"13456_CR148","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1212\/wnl.54.3.588","volume":"54","author":"PS Aisen","year":"2000","unstructured":"Aisen PS et al (2000) A randomized controlled trial of prednisone in Alzheimer\u2019s disease. Alzheimer\u2019s Disease Cooperative Study Neurology 54(3):588\u2013593. https:\/\/doi.org\/10.1212\/wnl.54.3.588","journal-title":"Alzheimer\u2019s Disease Cooperative Study Neurology"},{"issue":"1","key":"13456_CR149","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s1474-4422(07)70293-4","volume":"7","author":"P Bentham","year":"2008","unstructured":"Bentham P et al (2008) Aspirin in Alzheimer\u2019s disease (AD2000): a randomised open-label trial. Lancet Neurol 7(1):41\u201349. https:\/\/doi.org\/10.1016\/s1474-4422(07)70293-4","journal-title":"Lancet Neurol"},{"issue":"21","key":"13456_CR150","doi-asserted-by":"publisher","first-page":"2819","DOI":"10.1001\/jama.289.21.2819","volume":"289","author":"PS Aisen","year":"2003","unstructured":"Aisen PS et al (2003) Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA 289(21):2819\u20132826. https:\/\/doi.org\/10.1001\/jama.289.21.2819","journal-title":"JAMA"},{"issue":"6","key":"13456_CR151","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1038\/sj.npp.1300690","volume":"30","author":"LJ Thal","year":"2005","unstructured":"Thal LJ et al (2005) A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 30(6):1204\u20131215. https:\/\/doi.org\/10.1038\/sj.npp.1300690","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"13456_CR152","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s12974-020-01915-0","volume":"17","author":"BR Price","year":"2020","unstructured":"Price BR et al (2020) Therapeutic Trem2 activation ameliorates amyloid-beta deposition and improves cognition in the 5XFAD model of amyloid deposition. J Neuroinflammation 17(1):238. https:\/\/doi.org\/10.1186\/s12974-020-01915-0","journal-title":"J Neuroinflammation"},{"issue":"2","key":"13456_CR153","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12465","volume":"10","author":"J Cummings","year":"2024","unstructured":"Cummings J et al (2024) Alzheimer\u2019s disease drug development pipeline: 2024. Alzheimer\u2019s Dementia: Translational Research & Clinical Interventions 10(2):e12465. https:\/\/doi.org\/10.1002\/trc2.12465","journal-title":"Alzheimer\u2019s Dementia: Translational Research & Clinical Interventions"},{"issue":"4764","key":"13456_CR154","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1126\/science.3726555","volume":"233","author":"CA Czeisler","year":"1986","unstructured":"Czeisler CA et al (1986) Bright light resets the human circadian pacemaker independent of the timing of the sleep-wake cycle. Science 233(4764):667\u2013671. https:\/\/doi.org\/10.1126\/science.3726555","journal-title":"Science"},{"issue":"6901","key":"13456_CR155","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1038\/nature00965","volume":"418","author":"SM Reppert","year":"2002","unstructured":"Reppert SM, Weaver DR (2002) Coordination of circadian timing in mammals. Nature 418(6901):935\u2013941. https:\/\/doi.org\/10.1038\/nature00965","journal-title":"Nature"},{"issue":"5","key":"13456_CR156","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/0197-4580(95)00059-n","volume":"16","author":"A Satlin","year":"1995","unstructured":"Satlin A et al (1995) Circadian locomotor activity and core-body temperature rhythms in Alzheimer\u2019s disease. Neurobiol Aging 16(5):765\u2013771. https:\/\/doi.org\/10.1016\/0197-4580(95)00059-n","journal-title":"Neurobiol Aging"},{"issue":"4","key":"13456_CR157","doi-asserted-by":"publisher","DOI":"10.1093\/sleep\/zsz266","volume":"43","author":"I Guisle","year":"2020","unstructured":"Guisle I et al (2020) Circadian and sleep\/wake-dependent variations in tau phosphorylation are driven by temperature. Sleep 43(4):zsz266. https:\/\/doi.org\/10.1093\/sleep\/zsz266","journal-title":"Sleep"},{"issue":"6429","key":"13456_CR158","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1126\/science.aav2546","volume":"363","author":"JK Holth","year":"2019","unstructured":"Holth JK et al (2019) The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans. Science 363(6429):880\u2013884. https:\/\/doi.org\/10.1126\/science.aav2546","journal-title":"Science"},{"issue":"8","key":"13456_CR159","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1111\/jnc.15883","volume":"168","author":"JB Canever","year":"2023","unstructured":"Canever JB et al (2023) Circadian rhythm alterations affecting the pathology of neurodegenerative diseases. J Neurochem 168(8):1475\u20131489. https:\/\/doi.org\/10.1111\/jnc.15883","journal-title":"J Neurochem"},{"issue":"10","key":"13456_CR160","doi-asserted-by":"publisher","DOI":"10.1111\/acel.13704","volume":"21","author":"R Fan","year":"2022","unstructured":"Fan R et al (2022) Importance of Bmal1 in Alzheimer\u2019s disease and associated aging-related diseases: mechanisms and interventions. Aging Cell 21(10):e13704. https:\/\/doi.org\/10.1111\/acel.13704","journal-title":"Aging Cell"},{"key":"13456_CR161","doi-asserted-by":"publisher","unstructured":"Sheehan PW, et al (2023) An astrocyte BMAL1-BAG3 axis protects against alpha-synuclein and tau pathology. Neuron 111 (15): 2383\u20132398. https:\/\/doi.org\/10.1016\/j.neuron.2023.05.006","DOI":"10.1016\/j.neuron.2023.05.006"},{"key":"13456_CR162","doi-asserted-by":"publisher","unstructured":"Lananna BV, et al (2020) Chi3l1\/YKL-40 is controlled by the astrocyte circadian clock and regulates neuroinflammation and Alzheimer\u2019s disease pathogenesis. Sci Transl Med 12 (574): eaax3519. https:\/\/doi.org\/10.1126\/scitranslmed.aax3519","DOI":"10.1126\/scitranslmed.aax3519"},{"issue":"20","key":"13456_CR163","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2220551120","volume":"120","author":"CA McKee","year":"2023","unstructured":"McKee CA et al (2023) Circadian clock protein BMAL1 broadly influences autophagy and endolysosomal function in astrocytes. Proc Natl Acad Sci U S A 120(20):e2220551120","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"13456_CR164","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s12974-023-02727-8","volume":"20","author":"CA Iweka","year":"2023","unstructured":"Iweka CA et al (2023) Myeloid deficiency of the intrinsic clock protein BMAL1 accelerates cognitive aging by disrupting microglial synaptic pruning. J Neuroinflammation 20(1):48. https:\/\/doi.org\/10.1186\/s12974-023-02727-8","journal-title":"J Neuroinflammation"},{"issue":"21","key":"13456_CR165","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21217862","volume":"21","author":"ID Yoo","year":"2020","unstructured":"Yoo ID et al (2020) Elevated CLOCK and BMAL1 contribute to the impairment of aerobic glycolysis from astrocytes in Alzheimer\u2019s disease. Int J Mol Sci 21(21):7862. https:\/\/doi.org\/10.3390\/ijms21217862","journal-title":"Int J Mol Sci"},{"key":"13456_CR166","doi-asserted-by":"crossref","unstructured":"Toljan K, Homolak J (2021) Circadian changes in Alzheimer\u2019s disease: neurobiology, clinical problems, and therapeutic opportunities. Handbook Clin Neurol 179: 285\u2013300","DOI":"10.1016\/B978-0-12-819975-6.00018-2"},{"key":"13456_CR167","doi-asserted-by":"publisher","DOI":"10.3390\/biom11071004","author":"E Kim","year":"2021","unstructured":"Kim E et al (2021) Effects of the clock modulator Nobiletin on circadian rhythms and pathophysiology in female mice of an Alzheimer\u2019s disease model. Biomolecules. https:\/\/doi.org\/10.3390\/biom11071004","journal-title":"Biomolecules"},{"key":"13456_CR168","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.neurobiolaging.2020.02.020","volume":"91","author":"F Zhou","year":"2020","unstructured":"Zhou F et al (2020) Suvorexant ameliorates cognitive impairments and pathology in APP\/PS1 transgenic mice. Neurobiol Aging 91:66\u201375. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2020.02.020","journal-title":"Neurobiol Aging"},{"issue":"3","key":"13456_CR169","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1002\/alz.12035","volume":"16","author":"WJ Herring","year":"2020","unstructured":"Herring WJ et al (2020) Polysomnographic assessment of suvorexant in patients with probable Alzheimer\u2019s disease dementia and insomnia: a randomized trial. Alzheimers Dement 16(3):541\u2013551. https:\/\/doi.org\/10.1002\/alz.12035","journal-title":"Alzheimers Dement"},{"issue":"2","key":"13456_CR170","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/s1474-4422(03)00305-3","volume":"2","author":"JT O\u2019Brien","year":"2003","unstructured":"O\u2019Brien JT et al (2003) Vascular cognitive impairment. Lancet Neurol 2(2):89\u201398. https:\/\/doi.org\/10.1016\/s1474-4422(03)00305-3","journal-title":"Lancet Neurol"},{"issue":"9","key":"13456_CR171","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1093\/brain\/awt188","volume":"136","author":"JB Toledo","year":"2013","unstructured":"Toledo JB et al (2013) Contribution of cerebrovascular disease in autopsy confirmed neurodegenerative disease cases in the national Alzheimer\u2019s Coordinating Centre. Brain 136(9):2697\u20132706. https:\/\/doi.org\/10.1093\/brain\/awt188","journal-title":"Brain"},{"issue":"12","key":"13456_CR172","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/nm.3407","volume":"19","author":"B Obermeier","year":"2013","unstructured":"Obermeier B et al (2013) Development, maintenance and disruption of the blood-brain barrier. Nat Med 19(12):1584\u20131596. https:\/\/doi.org\/10.1038\/nm.3407","journal-title":"Nat Med"},{"issue":"2","key":"13456_CR173","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","volume":"85","author":"A Montagne","year":"2015","unstructured":"Montagne A et al (2015) Blood-brain barrier breakdown in the aging human Hippocampus. Neuron 85(2):296\u2013302. https:\/\/doi.org\/10.1016\/j.neuron.2014.12.032","journal-title":"Neuron"},{"issue":"10","key":"13456_CR174","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/jcbfm.2013.135","volume":"33","author":"MA Erickson","year":"2013","unstructured":"Erickson MA, Banks WA (2013) Blood-brain barrier dysfunction as a cause and consequence of Alzheimer\u2019s disease. J Cereb Blood Flow Metab 33(10):1500\u20131513. https:\/\/doi.org\/10.1038\/jcbfm.2013.135","journal-title":"J Cereb Blood Flow Metab"},{"issue":"1","key":"13456_CR175","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40478-015-0186-2","volume":"3","author":"LJ Blair","year":"2015","unstructured":"Blair LJ et al (2015) Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol Commun 3(1):8. https:\/\/doi.org\/10.1186\/s40478-015-0186-2","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"13456_CR176","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1146\/annurev-pathmechdis-030421-112756","volume":"17","author":"N Koutsodendris","year":"2022","unstructured":"Koutsodendris N et al (2022) Apolipoprotein E and Alzheimer\u2019s disease: findings, hypotheses, and potential mechanisms. Annu Rev Pathol Mech Dis 17(1):73\u201399. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-030421-112756","journal-title":"Annu Rev Pathol Mech Dis"},{"issue":"2","key":"13456_CR177","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3233\/jad-132480","volume":"41","author":"G Viticchi","year":"2014","unstructured":"Viticchi G et al (2014) Apolipoprotein E genotype and cerebrovascular alterations can influence conversion to dementia in patients with mild cognitive impairment. J Alzheimers Dis 41(2):401\u2013410. https:\/\/doi.org\/10.3233\/jad-132480","journal-title":"J Alzheimers Dis"},{"issue":"8","key":"13456_CR178","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.neubiorev.2013.05.006","volume":"37","author":"I Reinvang","year":"2013","unstructured":"Reinvang I et al (2013) APOE-related biomarker profiles in non-pathological aging and early phases of Alzheimer\u2019s disease. Neurosci Biobehav Rev 37(8):1322\u20131335. https:\/\/doi.org\/10.1016\/j.neubiorev.2013.05.006","journal-title":"Neurosci Biobehav Rev"},{"issue":"8","key":"13456_CR179","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1136\/jnnp-2012-303898","volume":"84","author":"K Rannikmae","year":"2013","unstructured":"Rannikmae K et al (2013) Genetics of cerebral amyloid angiopathy: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 84(8):901\u2013908. https:\/\/doi.org\/10.1136\/jnnp-2012-303898","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13456_CR180","doi-asserted-by":"publisher","unstructured":"Nelson PT, Pious NM, Jicha GA, Wilcock DM, Fardo DW, Estus S, Rebeck GW (2013) APOE-\u03b52 and APOE-\u03b54 correlate with increased amyloid accumulation in cerebral vasculature. J Neuropathol Exp Neurol 72(7): 708\u2013715. https:\/\/doi.org\/10.1097\/NEN.0b013e31829a25b9","DOI":"10.1097\/NEN.0b013e31829a25b9"},{"issue":"15","key":"13456_CR181","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1016\/j.jacc.2019.07.081","volume":"74","author":"M Cortes-Canteli","year":"2019","unstructured":"Cortes-Canteli M et al (2019) Long-term dabigatran treatment delays Alzheimer\u2019s disease pathogenesis in the TgCRND8 mouse model. J Am Coll Cardiol 74(15):1910\u20131923. https:\/\/doi.org\/10.1016\/j.jacc.2019.07.081","journal-title":"J Am Coll Cardiol"},{"key":"13456_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101619","volume":"77","author":"R Bai","year":"2022","unstructured":"Bai R et al (2022) Oxidative stress: the core pathogenesis and mechanism of Alzheimer\u2019s disease. Ageing Res Rev 77:101619. https:\/\/doi.org\/10.1016\/j.arr.2022.101619","journal-title":"Ageing Res Rev"},{"key":"13456_CR183","doi-asserted-by":"publisher","first-page":"797","DOI":"10.2147\/dddt.S130514","volume":"11","author":"G Ganguly","year":"2017","unstructured":"Ganguly G et al (2017) Proteinopathy, oxidative stress and mitochondrial dysfunction: cross talk in Alzheimer\u2019s disease and Parkinson\u2019s disease. Drug Des Devel Ther 11:797\u2013810. https:\/\/doi.org\/10.2147\/dddt.S130514","journal-title":"Drug Des Devel Ther"},{"issue":"14","key":"13456_CR184","doi-asserted-by":"publisher","first-page":"7697","DOI":"10.3390\/ijms22147697","volume":"22","author":"N Kim","year":"2021","unstructured":"Kim N, Lee HJ (2021) Redox-active metal ions and amyloid-degrading enzymes in Alzheimer\u2019s disease. Int J Mol Sci 22(14):7697. https:\/\/doi.org\/10.3390\/ijms22147697","journal-title":"Int J Mol Sci"},{"issue":"4","key":"13456_CR185","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s12017-011-8155-9","volume":"13","author":"Z Cai","year":"2011","unstructured":"Cai Z et al (2011) Oxidative stress and \u03b2-amyloid protein in Alzheimer\u2019s disease. Neuromolecular Med 13(4):223\u2013250. https:\/\/doi.org\/10.1007\/s12017-011-8155-9","journal-title":"Neuromolecular Med"},{"issue":"2","key":"13456_CR186","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1042\/bj20140772","volume":"463","author":"DA Butterfield","year":"2014","unstructured":"Butterfield DA et al (2014) Redox proteomics analysis to decipher the neurobiology of Alzheimer-like neurodegeneration: overlaps in down\u2019s syndrome and Alzheimer\u2019s disease brain. Biochem J 463(2):177\u2013189. https:\/\/doi.org\/10.1042\/bj20140772","journal-title":"Biochem J"},{"issue":"2","key":"13456_CR187","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3233\/jad-2010-100474","volume":"22","author":"G Ill-Raga","year":"2010","unstructured":"Ill-Raga G et al (2010) Amyloid-\u03b2 peptide fibrils induce nitro-oxidative stress in neuronal cells. J Alzheimers Dis 22(2):641\u2013652. https:\/\/doi.org\/10.3233\/jad-2010-100474","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"13456_CR188","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1471-4159.2008.05347.x","volume":"106","author":"PB Shelat","year":"2008","unstructured":"Shelat PB et al (2008) Amyloid beta peptide and NMDA induce ROS from NADPH oxidase and AA release from cytosolic phospholipase A2 in cortical neurons. J Neurochem 106(1):45\u201355. https:\/\/doi.org\/10.1111\/j.1471-4159.2008.05347.x","journal-title":"J Neurochem"},{"key":"13456_CR189","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.redox.2018.03.012","volume":"16","author":"E Sidlauskaite","year":"2018","unstructured":"Sidlauskaite E et al (2018) Mitochondrial ROS cause motor deficits induced by synaptic inactivity: implications for synapse pruning. Redox Biol 16:344\u2013351. https:\/\/doi.org\/10.1016\/j.redox.2018.03.012","journal-title":"Redox Biol"},{"issue":"1","key":"13456_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e12877","volume":"9","author":"W Wang","year":"2023","unstructured":"Wang W et al (2023) Vitamin D and neurodegenerative diseases. Heliyon 9(1):e12877. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e12877","journal-title":"Heliyon"},{"issue":"20","key":"13456_CR191","doi-asserted-by":"publisher","first-page":"12603","DOI":"10.3390\/ijms232012603","volume":"23","author":"D Mantle","year":"2022","unstructured":"Mantle D, Hargreaves IP (2022) Mitochondrial dysfunction and neurodegenerative disorders: role of nutritional supplementation. Int J Mol Sci 23(20):12603. https:\/\/doi.org\/10.3390\/ijms232012603","journal-title":"Int J Mol Sci"},{"key":"13456_CR192","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101756","volume":"82","author":"M George","year":"2022","unstructured":"George M et al (2022) Role of Nrf2 in aging, Alzheimer\u2019s and other neurodegenerative diseases. Ageing Res Rev 82:101756. https:\/\/doi.org\/10.1016\/j.arr.2022.101756","journal-title":"Ageing Res Rev"},{"issue":"3","key":"13456_CR193","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1006593","volume":"13","author":"B Lu","year":"2017","unstructured":"Lu B et al (2017) Direct Keap1-Nrf2 disruption as a potential therapeutic target for Alzheimer\u2019s disease. PLoS Genet 13(3):e1006593. https:\/\/doi.org\/10.1371\/journal.pgen.1006593","journal-title":"PLoS Genet"},{"issue":"3","key":"13456_CR194","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1007\/s11357-024-01118-y","volume":"46","author":"M Pszczo\u0142owska","year":"2024","unstructured":"Pszczo\u0142owska M et al (2024) Mitochondrial disorders leading to Alzheimer\u2019s disease\u2014perspectives of diagnosis and treatment. GeroScience 46(3):2977\u20132988. https:\/\/doi.org\/10.1007\/s11357-024-01118-y","journal-title":"GeroScience"},{"issue":"1","key":"13456_CR195","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1017\/s0033291708003681","volume":"39","author":"M Hamer","year":"2008","unstructured":"Hamer M, Chida Y (2008) Physical activity and risk of neurodegenerative disease: a systematic review of prospective evidence. Psychol Med 39(1):3\u201311. https:\/\/doi.org\/10.1017\/s0033291708003681","journal-title":"Psychol Med"},{"key":"13456_CR196","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2023.102127","volume":"92","author":"X Zhang","year":"2023","unstructured":"Zhang X et al (2023) Effect of physical activity on risk of Alzheimer\u2019s disease: a systematic review and meta-analysis of twenty-nine prospective cohort studies. Ageing Res Rev 92:102127. https:\/\/doi.org\/10.1016\/j.arr.2023.102127","journal-title":"Ageing Res Rev"},{"key":"13456_CR197","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101479","volume":"72","author":"S L\u00f3pez-Ortiz","year":"2021","unstructured":"L\u00f3pez-Ortiz S et al (2021) Exercise interventions in Alzheimer\u2019s disease: a systematic review and meta-analysis of randomized controlled trials. Ageing Res Rev 72:101479. https:\/\/doi.org\/10.1016\/j.arr.2021.101479","journal-title":"Ageing Res Rev"},{"issue":"5","key":"13456_CR198","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.jshs.2020.01.004","volume":"9","author":"A De la Rosa","year":"2020","unstructured":"De la Rosa A et al (2020) Physical exercise in the prevention and treatment of Alzheimer\u2019s disease. J Sport Health Sci 9(5):394\u2013404. https:\/\/doi.org\/10.1016\/j.jshs.2020.01.004","journal-title":"J Sport Health Sci"},{"key":"13456_CR199","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102655","volume":"104","author":"CVF de S\u00e1 Leit\u00e3o","year":"2025","unstructured":"de S\u00e1 Leit\u00e3o CVF et al (2025) Twelve weeks of exercise training improves cognitive status, physical performance and quality of life in Alzheimer\u2019s disease: a systematic review and meta-analysis. Ageing Res Rev 104:102655. https:\/\/doi.org\/10.1016\/j.arr.2025.102655","journal-title":"Ageing Res Rev"},{"key":"13456_CR200","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.605317","volume":"12","author":"E Parvin","year":"2020","unstructured":"Parvin E et al (2020) Dual-task training affect cognitive and physical performances and brain oscillation ratio of patients with Alzheimer\u2019s disease: a randomized controlled trial. Front Aging Neurosci 12:605317. https:\/\/doi.org\/10.3389\/fnagi.2020.605317","journal-title":"Front Aging Neurosci"},{"issue":"4","key":"13456_CR201","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanhl.2025.100706","volume":"6","author":"Z Xu","year":"2025","unstructured":"Xu Z et al (2025) Combined mind\u2013body physical exercise, cognitive training, and nurse-led risk factor modification to enhance cognition among older adults with mild cognitive impairment in primary care: a three-arm randomised controlled trial. Lancet Healthy Longev 6(4):100706. https:\/\/doi.org\/10.1016\/j.lanhl.2025.100706","journal-title":"Lancet Healthy Longev"},{"key":"13456_CR202","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2025.102785","volume":"109","author":"E V\u00e1squez-Carrasco","year":"2025","unstructured":"V\u00e1squez-Carrasco E et al (2025) Effectiveness of virtual reality interventions on quality of life, cognitive function and physical function in older people with Alzheimer\u2019s disease: a systematic review. Ageing Res Rev 109:102785. https:\/\/doi.org\/10.1016\/j.arr.2025.102785","journal-title":"Ageing Res Rev"},{"issue":"3","key":"13456_CR203","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/alz.12718","volume":"19","author":"BM Hampstead","year":"2022","unstructured":"Hampstead BM et al (2022) Toward rational use of cognitive training in those with mild cognitive impairment. Alzheimers Dement 19(3):933\u2013945. https:\/\/doi.org\/10.1002\/alz.12718","journal-title":"Alzheimers Dement"},{"issue":"1","key":"13456_CR204","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jalz.2008.10.008","volume":"5","author":"KV Papp","year":"2009","unstructured":"Papp KV et al (2009) Immediate and delayed effects of cognitive interventions in healthy elderly: a review of current literature and future directions. Alzheimers Dement 5(1):50\u201360. https:\/\/doi.org\/10.1016\/j.jalz.2008.10.008","journal-title":"Alzheimers Dement"},{"issue":"10","key":"13456_CR205","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/s1474-4422(04)00878-6","volume":"3","author":"JA Luchsinger","year":"2004","unstructured":"Luchsinger JA, Mayeux R (2004) Dietary factors and Alzheimer\u2019s disease. Lancet Neurol 3(10):579\u2013587. https:\/\/doi.org\/10.1016\/s1474-4422(04)00878-6","journal-title":"Lancet Neurol"},{"issue":"9","key":"13456_CR206","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.jalz.2014.11.009","volume":"11","author":"MC Morris","year":"2015","unstructured":"Morris MC et al (2015) Mind diet associated with reduced incidence of Alzheimer\u2019s disease. Alzheimers Dement 11(9):1007\u20131014. https:\/\/doi.org\/10.1016\/j.jalz.2014.11.009","journal-title":"Alzheimers Dement"},{"key":"13456_CR207","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.mam.2015.06.003","volume":"43\u201344","author":"J Rodakowski","year":"2015","unstructured":"Rodakowski J et al (2015) Non-pharmacological interventions for adults with mild cognitive impairment and early stage dementia: an updated scoping review. Mol Aspects Med 43\u201344:38\u201353. https:\/\/doi.org\/10.1016\/j.mam.2015.06.003","journal-title":"Mol Aspects Med"},{"issue":"1","key":"13456_CR208","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/s12974-024-03080-0","volume":"21","author":"M Poxleitner","year":"2024","unstructured":"Poxleitner M et al (2024) Western diet increases brain metabolism and adaptive immune responses in a mouse model of amyloidosis. J Neuroinflammation 21(1):129. https:\/\/doi.org\/10.1186\/s12974-024-03080-0","journal-title":"J Neuroinflammation"},{"issue":"11","key":"13456_CR209","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1002\/alz.13007","volume":"19","author":"AH Dilmore","year":"2023","unstructured":"Dilmore AH et al (2023) Effects of a ketogenic and low-fat diet on the human metabolome, microbiome, and foodome in adults at risk for Alzheimer\u2019s disease. Alzheimers Dement 19(11):4805\u20134816. https:\/\/doi.org\/10.1002\/alz.13007","journal-title":"Alzheimers Dement"},{"key":"13456_CR210","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2021.101397","volume":"70","author":"A Wi\u0119ckowska-Gacek","year":"2021","unstructured":"Wi\u0119ckowska-Gacek A et al (2021) Western diet as a trigger of Alzheimer\u2019s disease: from metabolic syndrome and systemic inflammation to neuroinflammation and neurodegeneration. Ageing Res Rev 70:101397. https:\/\/doi.org\/10.1016\/j.arr.2021.101397","journal-title":"Ageing Res Rev"},{"key":"13456_CR211","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ebiom.2019.08.032","volume":"47","author":"R Nagpal","year":"2019","unstructured":"Nagpal R et al (2019) Modified Mediterranean-ketogenic diet modulates gut microbiome and short-chain fatty acids in association with Alzheimer\u2019s disease markers in subjects with mild cognitive impairment. EBioMedicine 47:529\u2013542. https:\/\/doi.org\/10.1016\/j.ebiom.2019.08.032","journal-title":"EBioMedicine"},{"issue":"6","key":"13456_CR212","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70364","volume":"21","author":"E Nolan","year":"2025","unstructured":"Nolan E et al (2025) The association between poor sleep health and Alzheimer\u2019s disease structural neuroimaging biomarkers. Alzheimers Dement 21(6):e70364. https:\/\/doi.org\/10.1002\/alz.70364","journal-title":"Alzheimers Dement"},{"issue":"7003","key":"13456_CR213","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/4371220a","volume":"430","author":"L Nelson","year":"2004","unstructured":"Nelson L (2004) Neuroscience: while you were sleeping. Nature 430(7003):962\u2013964. https:\/\/doi.org\/10.1038\/4371220a","journal-title":"Nature"},{"issue":"9","key":"13456_CR214","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.scib.2025.03.023","volume":"70","author":"T Wei","year":"2025","unstructured":"Wei T et al (2025) Coupled sleep rhythm disruption predicts cognitive decline in Alzheimer\u2019s disease. Sci Bull 70(9):1491\u20131503. https:\/\/doi.org\/10.1016\/j.scib.2025.03.023","journal-title":"Sci Bull"},{"issue":"7063","key":"13456_CR215","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1038\/nature04286","volume":"437","author":"R Stickgold","year":"2005","unstructured":"Stickgold R (2005) Sleep-dependent memory consolidation. Nature 437(7063):1272\u20131278. https:\/\/doi.org\/10.1038\/nature04286","journal-title":"Nature"},{"issue":"3","key":"13456_CR216","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70096","volume":"21","author":"CL Chen","year":"2025","unstructured":"Chen CL et al (2025) Associations among sleep quality, sleep duration, and Alzheimer\u2019s disease biomarkers: a systematic review and meta-analysis. Alzheimers Dement 21(3):e70096. https:\/\/doi.org\/10.1002\/alz.70096","journal-title":"Alzheimers Dement"},{"key":"13456_CR217","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2021.101556","volume":"60","author":"AJ Scott","year":"2021","unstructured":"Scott AJ et al (2021) Improving sleep quality leads to better mental health: a meta-analysis of randomised controlled trials. Sleep Med Rev 60:101556. https:\/\/doi.org\/10.1016\/j.smrv.2021.101556","journal-title":"Sleep Med Rev"},{"issue":"6","key":"13456_CR218","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac257","volume":"4","author":"J Blackman","year":"2022","unstructured":"Blackman J et al (2022) Cross-sectional and longitudinal association of sleep and Alzheimer biomarkers in cognitively unimpaired adults. Brain Commun 4(6):fcac257. https:\/\/doi.org\/10.1093\/braincomms\/fcac257","journal-title":"Brain Commun"},{"key":"13456_CR219","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2020.615838","volume":"12","author":"Y Gao","year":"2021","unstructured":"Gao Y et al (2021) Sleep disturbance is associated with higher plasma A\u03b2 levels in cognitively normal adults\u2014a population-based cross-sectional study. Front Aging Neurosci 12:615838. https:\/\/doi.org\/10.3389\/fnagi.2020.615838","journal-title":"Front Aging Neurosci"},{"issue":"10","key":"13456_CR220","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1001\/jamaneurol.2021.2876","volume":"78","author":"JR Winer","year":"2021","unstructured":"Winer JR et al (2021) Association of short and long sleep duration with amyloid-\u03b2 burden and cognition in aging. JAMA Neurol 78(10):1187\u20131196. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2876","journal-title":"JAMA Neurol"},{"issue":"12","key":"13456_CR221","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/s1474-4422(24)00402-2","volume":"23","author":"G May\u00e0","year":"2024","unstructured":"May\u00e0 G et al (2024) Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series. Lancet Neurol 23(12):1238\u20131251. https:\/\/doi.org\/10.1016\/s1474-4422(24)00402-2","journal-title":"Lancet Neurol"},{"key":"13456_CR222","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2024.102457","volume":"100","author":"U Mukherjee","year":"2024","unstructured":"Mukherjee U et al (2024) Mechanisms, consequences and role of interventions for sleep deprivation: focus on mild cognitive impairment and Alzheimer\u2019s disease in elderly. Ageing Res Rev 100:102457. https:\/\/doi.org\/10.1016\/j.arr.2024.102457","journal-title":"Ageing Res Rev"},{"issue":"9212","key":"13456_CR223","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/s0140-6736(00)02113-9","volume":"355","author":"L Fratiglioni","year":"2000","unstructured":"Fratiglioni L et al (2000) Influence of social network on occurrence of dementia: a community-based longitudinal study. The Lancet 355(9212):1315\u20131319. https:\/\/doi.org\/10.1016\/s0140-6736(00)02113-9","journal-title":"The Lancet"},{"issue":"7","key":"13456_CR224","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.2105\/ajph.2007.115923","volume":"98","author":"VC Crooks","year":"2008","unstructured":"Crooks VC et al (2008) Social network, cognitive function, and dementia incidence among elderly women. Am J Public Health 98(7):1221\u20131227. https:\/\/doi.org\/10.2105\/ajph.2007.115923","journal-title":"Am J Public Health"},{"key":"13456_CR225","doi-asserted-by":"publisher","unstructured":"Wilson RS, Krueger KR, Arnold SE, Schneider JA, Kelly JF, Barnes LL, Tang Y, Bennett DA (2007 ) Loneliness and risk of Alzheimer disease. Arch Gen Psychiatry 64(2): 234\u2013240. https:\/\/doi.org\/10.1001\/archpsyc.64.2.234","DOI":"10.1001\/archpsyc.64.2.234"},{"issue":"2","key":"13456_CR226","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000089919","volume":"21","author":"A Karp","year":"2006","unstructured":"Karp A et al (2006) Mental, physical and social components in leisure activities equally contribute to decrease dementia risk. Dementia Geriatr Cogn Disord 21(2):65\u201373. https:\/\/doi.org\/10.1159\/000089919","journal-title":"Dementia Geriatr Cogn Disord"},{"key":"13456_CR227","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.arr.2015.04.006","volume":"22","author":"JS Kuiper","year":"2015","unstructured":"Kuiper JS et al (2015) Social relationships and risk of dementia: a systematic review and meta-analysis of longitudinal cohort studies. Ageing Res Rev 22:39\u201357. https:\/\/doi.org\/10.1016\/j.arr.2015.04.006","journal-title":"Ageing Res Rev"},{"issue":"2","key":"13456_CR228","doi-asserted-by":"publisher","first-page":"665","DOI":"10.3233\/jad-201442","volume":"80","author":"L-X Shen","year":"2021","unstructured":"Shen L-X et al (2021) Social isolation, social interaction, and Alzheimer\u2019s disease: a Mendelian randomization study. J Alzheimers Dis 80(2):665\u2013672. https:\/\/doi.org\/10.3233\/jad-201442","journal-title":"J Alzheimers Dis"},{"key":"13456_CR229","doi-asserted-by":"publisher","unstructured":"Marx, J. (2005) Alzheimer\u2019s disease. Play and exercise protect mouse brain from amyloid buildup. Science 307(5715): 1547. https:\/\/doi.org\/10.1126\/science.307.5715.1547.","DOI":"10.1126\/science.307.5715.1547"},{"issue":"6406","key":"13456_CR230","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan8821","volume":"361","author":"SH Choi","year":"2018","unstructured":"Choi SH et al (2018) Combined adult neurogenesis and BDNF mimic exercise effects on cognition in an Alzheimer\u2019s mouse model. Science 361(6406):eaan8821. https:\/\/doi.org\/10.1126\/science.aan8821","journal-title":"Science"},{"issue":"6429","key":"13456_CR231","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1126\/science.aaw5583","volume":"363","author":"W Noble","year":"2019","unstructured":"Noble W (2019) Sleep well to slow Alzheimer\u2019s progression? Science 363(6429):813\u2013814. https:\/\/doi.org\/10.1126\/science.aaw5583","journal-title":"Science"},{"issue":"6","key":"13456_CR232","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1093\/advances\/nmz054","volume":"10","author":"AC van den Brink","year":"2019","unstructured":"van den Brink AC et al (2019) The Mediterranean, dietary approaches to stop hypertension (DASH), and Mediterranean-DASH intervention for neurodegenerative delay (MIND) diets are associated with less cognitive decline and a lower risk of Alzheimer\u2019s disease\u2014a review. Adv Nutr 10(6):1040\u20131065. https:\/\/doi.org\/10.1093\/advances\/nmz054","journal-title":"Adv Nutr"},{"key":"13456_CR233","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyg.2022.1034454","volume":"13","author":"S Boukarras","year":"2022","unstructured":"Boukarras S et al (2022) Bringing social interaction at the core of organizational neuroscience. Front Psychol 13:1034454. https:\/\/doi.org\/10.3389\/fpsyg.2022.1034454","journal-title":"Front Psychol"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13456-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13456-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13456-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T01:03:10Z","timestamp":1761699790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13456-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":233,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["13456"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13456-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"29 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}],"article-number":"705"}}